Consensus community valuation
Average Intrinsic Value
Undervalued by
Active Member Straws
#Director Buying
Added 5 months ago

Some more on-market purchases from Directors. The most notable is from long standing director Mark McConnell, the second largest shareholder.

He purchased a further 104,600 shares at $4.77 each on the 19/2/20 (about $500k worth). He owns around 12% of the entire company.

Directors Robert Alexander and Peter Leahy purchased $35k and $47k on the same day, respectively. 

Read More
#COVID-19 Update
Added 4 months ago

Citadel has updated shareholders on the impacts to date from the coronavirus crisis.

Key points:

  • No significant projects or contracts have been delayed or cancelled, so far.
  • Customers are predominately from Government and Health sectors that are long-term contracts and for business critical software applications.
  • Citadel manages 42% of Australia's public pathology records, and is working with Healthcare providers to adapt to new tech that supports virus testing.
  • The company is planning on reducing opex, delay any non-essential investment and manage liquidity and cash flow within debt covenants 
  • Wellbeing is seeing opportunities arise across various products and services. 70% of its revenues are recurring, genereated form long-term contracts.
  • Post merger, Citadel expetcs to have $10m in cash and an undrawn facility for a further $10m
  • The company will still pay its interim dividend.

ASX announcement here

Read More
Added 4 months ago

Citadel has been punished more than most during this sell down. 

Shares have lost over 70% since Feb 17.

One of my best Strawman recommendations ever...

With health now a major segment, the coronavirus is going to have a direct impact. While it may be true that a lot of the health segment has high margin and recurring revenues, it's not going to be easy to make new sales into an overstretched and critically under-resourced health system. We'll also get to see just how recurring much of those revenues are.

The other problem is that around 2/3rds of revenues come from services and consulting - and demand for services is likely to take a massive hit over the coming year as customers focus on bigger priorities.

And all this just as the company took on more debt to fund the acquisition of Wellbeing, and now has a worthless share purchase plan following the institutional raise.

With a lot of long-standing government contracts, I had assumed that Citadel could survive a downturn, but I hadnt accounted for such a material shock.

This recommendation is very much under review.

Read More
#Capital Raise Troubles
Last edited 4 months ago

Citadel announced the acquisition of UK based health-tech company Wellebing for an enterprise value of $198m. The cash required was $189m, of which $127m would be raised through the issue of new shares.

They also took on $90m loan and $10m working capital facility. 

On 27th of Feb, Citadel said it had already raised $34m from an unconditional placement of shares to institutional and sophisticated investors, and "firm commitments" for the $93m to be raised through the conditional placement -- which will be voted on at an Extraordinary General Meeting (EGM) on March 30

Given the current market price, you have to wonder how "firm" those commitments really are! The retail SPP was also looking to raise around $10m, but that's not going to happen. 

HOWEVER, the ASX announcement on the 19th Feb says the institutional component was underwritten by Royal Bank of Canada. But i'm not sure that means Citadel still gets $4.65 per share given it still needs to be put to an EGM. (does anyone know?)

If this isnt the case, it looks like they will need to issue a lot more shares to raise the same money. At the current price, around 31m in total, compared to the original 20m for the conditional placement.

So we are now looking at a post acquisition share count of ~88m, versus the originally expected ~77m (assuming cash is raised at $3 per share -- it could well be lower!)

Effectively this makes the acquisition cost of Wellbeing much more expensive.

Read More
#Contract Update
Last edited 5 months ago


The Dept. of Defense has elected to exercise its extension options, which will take the support contracts through to July 2021.

The DoD is expected to soon issue a tender for the longer term sustainment contract. Citadel is hopefully well placed to win this work too (but we will see).

Citadel has also moved from preferred supplier status to a ful contract with Genovic. This is valued at $500k for the initail stages, with options to extend.

Full ASX annoucement here

On another note, it's also encouranging to see Pie Funds (a NZ based fund manager with a solid track record) increase its stake from 7.42% to 9.45% last week.


Read More
#Recent Buys
Added a month ago

Wilson Asset Management buying in over May and June now own 6.05%

Read More
#HY20 Results
Last edited 5 months ago

A lot to digest here. Share market reaction is brutal (down ~20% after open), but there's some context to be aware of. 

Starting with the results:

Total revenue for the 6 moths to December 31 was 25% higher at 61.1m. However, exlcuding the contribution from the recent Noventus Acquisition, revenue was essentially flat from the previous corresponding period.

(In saying that, it looks like that acquisition is working out well -- they paid only $5.7m for that business last year, which was generating $17.5m in full year revenues and 2.1m in EBITDA)

Reduced gross margins and operating margins resulted in a 5.3% decrease in EBITDA to $12.5m

Although none of this sounds great, Citadel has clearly articulated it's strategic shift towards its software segment -- which has lower margins than services revenue, but longer durations. And in this segment, revenue was up 18%. The Noventus business also operates at lower margins, which impacts the group average.

Post the Wellbeing acquisition (detailed in another Straw), the group expects 63% of total revenues to come from the Software segment, up from 47%

The company reiterated guidance of revenue and EBITDA growth for the full year, with ex-Noventus margins "broadly consistent". Specifically, revenue of $128-132m and EBITDA of $28-30m for the existing business.

On a pro-forma basis, including Wellbeing for a full year, FY20 group revenues and EBITDA would be $163.1m and $42.9m, respectively.

The purchase of Wellbeing is expected to be EPS accretive in FY20 and FY21, growing at upper single digit rates.

Although shares dropped significantly on the open, it's really just lost the last few weeks of gains, and remain above the issue price of new shares (for Wellbeing acquisition, of $4.65, a 12.5% discount to the 10-day volume weighted average price. 

I still remain optimistic towards Citadel and hold on my Strawman scorecard.



Read More
#Wellbeing acquisition
Last edited 5 months ago

Citadel has acquired UK based health software company Wellbeing for $198m. It provides radiology and maternity workflow solutions in the UK to 150 clients and has a large market share. 

The company generates around $31m in revenue and $12.5m in EBITDA. Revenues and margins have been growing well in recent years. 

It's a very BIG move, increasing the EBITDA by almsot 50%, and the share count by ~60%. It significantly expands their healthcare revenues and gives them an established fotthold in the UK market. Importantly, most revenue is recurring in nature and at better margins. It also has big cross-sell potential.

After the deal, the group will have ~$90m in debt (debt/equity of 42%) and $16m in cash.

All told, it seems to make a lot of sense. Citadel is well practiced at acquisitions, and this latest one improves the financial profile and business quality. As always, there could be digestion pains, and operating in a new geography is always tough.

At 13.2x forward EV/EBITDA, it's not cheap, but not unreasonable if Wellbeing can sustain its recent growth and Citadel can effectively cross-sell it's products into the UK market.

More info in the company presentation slides here 


Read More
Last edited 4 months ago

On a few traders radars today +40% at one point?


Directors inside willing to pay on market at double the current SP always a nice sign.


Long term stocks as such I think will be front of the queue once equities are back in favour.

Read More
#FY19 Results
Last edited 5 months ago

Results came in almost exactly at the midpoint of guidance.

Nevertheless, it was a tough year with a more than 40% drop in profits. This is however largely explained by the trasnition to a SaaS model and the delay (but not cancellation) of key projects.

Costs were flat, debt was reduced and Saas Revenue was up strongly.

Profit was lower than i had anticipated, so i have reduced my valuation. Nevertheless, shares remain decent value for a long term hold.

Results presentation can be viewed here

Read More
#Price Targets
Last edited 6 months ago

Morning star - 6.665 (fair value)

RBC Capital - 9.50 

Bell Potter - 5.50 

Discounted cash flow model suggests a little bit lower about 5.25

A big buy from Microequities Assest Managemnent suggest they are quite bullish on the stock.

I am quietly confident the earnings will have a big turn around in comparison to last years disappointing results. 

Read More